Trial Profile

A phase 1 study to assess RNAT-89 (BLA-761423)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Aug 2024 New trial record
19 Aug 2024 According to a RNA Therapeutics media release, company announced that it has received a written response to its Pre-Investigational New Drug Application (pre-IND) questions submitted to the U.S. Food and Drug Administration (FDA) regarding the development of RNAT-89 (BLA-761423) indicated for the treatment of anemia due to chronic kidney disease (CKD) and non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com